Are the effects of α-glucosidase inhibitors on cardiovascular events related to elevated levels of hydrogen gas in the gastrointestinal tract?
References and further reading may be available for this article. To view references and further reading you must
purchase this article.
Yoshihiko Suzukia, Motoaki Sanoc, , , Kentaro Hayashidac, Ikuroh Ohsawaa, b, Shigeo Ohtaa and Keiichi Fukudac
aDepartment of Biochemistry and Cell Biology, Institute of Development and Aging Science, Graduate School of Medicine, Nippon Medical School, Kawasaki City 211-8533, Japan
bThe Center of Molecular Hydrogen Medicine, Institute of Development and Aging Science, Graduate School of Medicine, Nippon Medical School, Kawasaki City 211-8533, Japan
cDepartment of Regenerative Medicine and Advanced Cardiac Therapeutics, Keio University School of Medicine, Tokyo 160-8582, Japan
Available online 8 June 2009.
Abstract
The major side-effect of treatment with α-glucosidase inhibitors, flatulence, occurs when undigested carbohydrates are fermented by colonic bacteria, resulting in gas formation. We propose that the cardiovascular benefits of α-glucosidase inhibitors are partly attributable to their ability to neutralise oxidative stress via increased production of H2 in the gastrointestinal tract. Acarbose, which is an α-glucosidase inhibitor, markedly increased H2 production, with a weaker effect on methane production. Our hypothesis is based on our recent discovery that H2 acts as a unique antioxidant, and that when inhaled or taken orally as H2-dissolved water it ameliorates ischaemia–reperfusion injury and atherosclerosis development.
Keywords: α-Glucosidase inhibitors; Type 2 diabetes; Hydrogen gas; Antioxidant
Corresponding author. Address: Department of Regenerative Medicine and Advanced Cardiac Therapeutics, Keio University School of Medicine, 35 Shinanomachi Shinjuku-ku, Tokyo 160-8582, Japan. Fax: +81 3 5363 3875.
全文下在这里